February 18, 2023 December 30, 2022 December 10, 2021 September 15, 2021 
The BioMedomics COVID-19 IgG/IgM Rapid Test is a rapid, point-of-care (POC) lateral flow immunoassay (LFA) that detects antibodies to the SARS-CoV-2 spike protein receptor-binding domain
Morrisville, NC, USA – BioMedomics, a renowned player in the medical diagnostics field, has recently received authorization from Health Canada’s Medical Device Directorate to import
BioMedomics is an ISO 13485 certified company committed to meeting unmet market needs by developing innovative point-of-care diagnostic tests which provide immediate answers to individuals
BioMedomics CoV-SCAN Rapid Antigen Test demonstrated high sensitivity and specificity for numerous SARS-CoV-2 variants, including Omicron and Delta, in a peer-reviewed point-of-care clinical evaluation Recently
BioMedomics, Inc. is proud to announce that the BSI Group of America has accredited and recertified our ISO 13485:2016 certification. The certification of compliance with
BioMedomics, Inc. is proud to announce that the BSI Group of America has accredited and recertified our ISO 13485:2016 certification. The certification of compliance with
An article about BioMedomics’s COVID-19 IgM/IgG Rapid Antibody Test that several employees of BioMedomics, Inc., worked on has been awarded as one of the top
BioMedomics, Inc. is proud to announce its ISO 13485:2016 certificate has expanded in scope to include the design, development and manufacturing of COVID-19 rapid tests.
We are excited to announce that the National Institute for Food and Drug Surveillance (INVIMA) has given BioMedomics, Inc. authorization to sell and distribute our
We are excited to announce that the Therapeutic Goods Administration, a branch of the Department of Health in the Australian Government, has given BioMedomics, Inc.